This Arthritis Breakthrough Could Be the Shot Your Portfolio Needs

This little-known biotech just grabbed the FDA’s attention with a fast-tracked approach to treating stubborn autoimmune cases.

If upcoming data delivers, its off-the-shelf cell therapy could reshape how rheumatoid arthritis is treated… and how this stock trades.

Crypto regulation finally arrived—and it’s a game changer.

Clear oversight of digital assets means institutions no longer hesitate.

The market just broke $4 trillion, and the flood of new money is far from over.

Our FREE Crypto Revolution book is your roadmap to this historic shift.

[Click here to secure your copy + $788 bonuses]

© 2025 Boardwalk Flock LLC. All Rights Reserved. 2382 Camino Vida Roble, Suite I Carlsbad, CA 92011, United States

The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.

Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.

U.S. stocks rose Friday after better-than-expected bank earnings and a rebound in regional lenders calmed credit risk fears, while a softer stance from President Trump on China tariffs fueled optimism ahead of trade talks.

Abbott Laboratories (NYSE: ABT) slipped in October, and the market barely waited to ask why.

Analysts, institutions, and dividend hunters, however, see that pullback as the buying opportunity they’ve been waiting for.

If you’re watching from the sidelines, this might be one of those rare times when a little red on the chart looks green in disguise.

Abbott’s fundamentals are strong, its growth steady, and its long-term setup healthier than your daily vitamin routine.

Still the Doctor’s Favorite

The company’s Q3 report didn’t thrill Wall Street, but it didn’t disappoint either. Revenue ticked higher, margins improved, and medical devices continued to be the star of the show.

You can see how Abbott’s diversified business gives it a cushion when one segment slows. The beauty of that balance is stability, which matters most when the rest of the healthcare sector feels volatile.

A Dividend That Never Misses a Dose

Abbott has raised its dividend for over 50 straight years, earning its spot as one of Wall Street’s most dependable payers.

The payout is growing, the cash flow looks strong, and management isn’t showing any signs of tightening the purse strings.

If you’re the type who values patience over speed, Abbott’s next move might just prove worth the wait.

BlackRock (NYSE: BLK) is taking its money market empire into digital territory.

The firm is reworking its Select Treasury-Based Liquidity Fund to qualify as a reserve asset for U.S. stablecoin issuers, effectively merging the world of regulated finance with blockchain-backed digital dollars.

This move changes the game.

BlackRock is providing stablecoin providers with a compliant home for their reserves, allowing you to see in real time how traditional cash management meets the new internet of money.

The $1 Trillion Bridge

To make it work, the fund is shedding agency holdings, shortening Treasury maturities, and adding overnight repo agreements.

That turns it into a digital-ready version of Wall Street’s safest instrument.

You can almost feel the strategy click. BlackRock is positioning itself as the bridge between institutional safety and crypto innovation.

Every transaction on that bridge could eventually trace back to them.

Money Is Getting an Upgrade

This isn’t about chasing crypto hype; it’s about owning the plumbing that keeps it running.

BlackRock’s redesigned fund shows how programmable money and traditional finance are finally shaking hands.

You might think you’re just scrolling, but what you’re really seeing is the future of trust being built; one blockchain-backed dollar at a time.

Your portfolio doesn’t need dozens of winners. Sometimes, just a few right picks can do the heavy lifting.

That’s the thinking behind our newest report: 5 Stocks Set to Double.

These companies were chosen because they combine:

And while no outcome can be guaranteed, previous reports like this have spotlighted stocks before massive moves—+175%, +498%, even +673%.¹

Now, you can get the latest edition absolutely free—until midnight tonight.

[Click here to download instantly]

This window won’t stay open. Act now.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Oracle (NYSE: ORCL) has made its intentions clear as it wants to dominate the AI infrastructure race.

The company expects its cloud business to hit $166 billion in annual sales by 2030, turning what was once a software story into a full-blown AI revolution.

If you’ve been watching the company evolve, you know this isn’t a side hustle.

Oracle is putting its entire muscle behind becoming the backbone of digital infrastructure, the invisible engine powering the world’s biggest workloads.

Building the Brain of the Internet

Partnerships with social platforms, AI labs, and massive enterprise clients are fueling Oracle’s next act.

Each new deal strengthens its position as the go-to platform for compute-heavy industries chasing efficiency and scale.

You can feel the shift every time Oracle announces another hyperscale data center or AI collaboration.

It’s a play for relevance that puts Oracle shoulder to shoulder with Amazon, Google, and Microsoft in the cloud arena.

The Future Looks Scalable

Oracle’s next chapter feels more like a reinvention than a routine upgrade.

The company is shifting from selling software to running the digital backbone that modern businesses depend on.

If you care about where the world’s next big leap in computing will come from, Oracle is quietly building the runway for it.

Every new cloud deployment and AI deal adds proof that the company isn’t chasing the future—it’s helping design it.

👉 Click here to get our closing report to your cell for free!

Artiva Biotherapeutics Inc [ARTV] $6.01 (+116.97%)

Artiva surged after receiving FDA Fast Track Designation for its cell therapy AlloNK in refractory rheumatoid arthritis, with pivotal trial discussions expected in 2026.

Kezar Life Sciences Inc [KZR] $6.36 (+52.15%)

Kezar spiked after launching a strategic review following FDA pushback on its autoimmune hepatitis trial, signaling potential M&A or asset monetization.

Virnetx Holding Corp [VHC] $23.87 (+40.41%)

VirnetX rose after landing a GSA Schedule contract, making it an approved cybersecurity and secure communications provider for U.S. government agencies.

Sensei Biotherapeutics Inc [SNSE] $11.71 (-33.37%)

Sensei fell after its cancer drug solnerstotug showed no responses at the lower dose and mixed efficacy in a small Phase 1/2 trial.

Obook Holdings Inc [OWLS] $39.50 (-28.89%)

OBOOK tumbled as investors took profits following its blockbuster Nasdaq debut, with the blockchain stock retreating sharply from its $68 opening high.

Solana Company [HSDT] $7.76 (-23.24%)

Solana Company shares plunged alongside weakness in the Solana coin, which fell amid a broader decline in the crypto market that weighed on sentiment for crypto-exposed equities.

In times of uncertainty and rapid shifts, short-term opportunities can create outsized returns.

Our team has just completed a data-driven analysis to identify 7 high-potential stocks showing strong indicators of breakout performance this month.

These stocks aren’t just guesses.

They’re based on a strategy that has outperformed the market for over 30 years.

Each one passed a strict screening process and now ranks among the top performers tracked by a proprietary model used by experienced investors.

The full list is now available in a brand-new special report—and it's free.

The opportunity to act before momentum hits is limited.

You don’t want to be late to the trend.

Click here to get your free copy of this must-see stock list and take your next step with confidence.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.